
Opinion|Videos|April 3, 2025
Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows potential beyond first-line treatment, offering efficacy in patients progressing on systemic therapies, with emerging data supporting its role in treatment sequencing.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What treatment considerations arise when a patient progresses and requires second-line therapy?
- Discuss the potential for lenvatinib beyond first-line treatment in patients progressing on systemic therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
4
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
5



















